Calliditas Confident Despite Cutting Tarpeyo Sales Guidance
Hopes Rest On Getting Full Approval From FDA
The Swedish biotech’s immunoglobulin A nephropathy therapy Tarpeyo is still selling well but “market access friction” is slowing growth. As US regulators grant a priority review to its data package for full approval, Calliditas’s prospects look promising.
